Developing a new gene therapy for treating muscle degeneration in older adults
Official title: Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis
Funded at Aavogen, INC. · NIH-10709907 · Data updated 2026-11-12
This study is testing a new gene therapy called AVGN7 to help older adults with sporadic inclusion body myositis (IBM) by boosting muscle strength and function, with hopes of making life easier and more enjoyable for those living with this challenging condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aavogen, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | September 30, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $973,558 |
| NIH project number | 5R44AG079825-02 |
| Project ID | NIH-10709907 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults diagnosed with sporadic inclusion body myositis.
✕Less likely to help
Patients with muscle degeneration due to genetic mutations or other non-inflammatory causes may not benefit from this research.
What this research studies
This research focuses on creating a novel gene therapy aimed at treating sporadic inclusion body myositis (IBM), a rare disease that primarily affects older adults and leads to progressive muscle degeneration. The approach involves using a gene therapeutic called AVGN7, which enhances muscle mass and function by suppressing certain signaling pathways that contribute to muscle wasting. The research includes preclinical studies to prepare for clinical trials, with the goal of providing a durable solution for patients suffering from this debilitating condition. If successful, this therapy could significantly improve the quality of life for those affected by IBM.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that enhances muscle mass and function for patients with inclusion body myositis.
How similar studies have gone: Other research has shown promise in using gene therapy for muscle-related diseases, indicating potential success for this novel approach.
Where this research is happening
-
Aavogen, INC.
Rockville, United States Active
Researchers
- Principal investigator: Rodgers, Buel — Aavogen, INC.
- Study coordinator: Rodgers, Buel
Related research
Other NIH-funded projects on the same topics.
-
Myositis-ILD Risk Prediction: How ILD Progresses in Myositis Patients
A study to build better tools that predict how lung disease linked to myositis will behave in diverse patients.
-
Autoantibodies and membrane repair in myositis
A blood and tissue study seeks to understand how immune reactions against muscle repair proteins contribute to inflammatory myositis, with the goal of guiding better treatments for people with this condition.
-
Why chikungunya causes long-lasting joint and muscle pain
This work looks at how chikungunya virus can linger in joint and muscle cells and keep causing pain for people who had the infection.
-
Autoantibodies against muscle membrane repair proteins in myositis
This work looks at whether people with myositis have antibodies that attack proteins that fix damaged muscle cell membranes and how that may cause muscle inflammation and weakness.
-
Predicting lung disease outcomes in people with myositis
This project combines medical information and genetic markers to predict which people with myositis will have worsening interstitial lung disease.
-
Cancer risk in inflammatory muscle disease (myositis)
This project looks for signs in people with idiopathic inflammatory myopathies that show whether they have or might develop cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.